1. Scrip
  2. >>Therapy Areas

Japanese generic listing includes cefdinir products

 
• By Ian Haydock

This year's second listing of generic products in Japan's national insurance reimbursement tariff has seen [C#198600364:Astellas]'s Cefzon (cefdinir) opened up to its first competition from such products.

This year's second listing of generic products in Japan's national insurance reimbursement tariff has seen Astellas's Cefzon (cefdinir) opened up to its first competition from such products.

Six of the 14 newly listed presentations were for the paediatric form of the oral cephalosporin, sales of which Astellas...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.